Method of quickly producing antibodies against avian influenza and maintain antibody titer of duck

Patent metadata

Field	Value
Publication number	US-10124057-B2
Application number	US-201715444305-A
Country	US
Kind code	B2
Filing date	Feb 27, 2017
Priority date	Feb 25, 2016
Publication date	Nov 13, 2018
Grant date	Nov 13, 2018

Abstract

The present invention provides a method for enabling ducklings to quickly produce anti-avian influenza antibodies and maintain antibody titer, including: step 1) the first immunization is performed on ducklings at the age of 5 to 15 days: each duckling is inoculated with an avian influenza inactivated antigen in an abdomen, and simultaneously intramuscularly or subcutaneously immunized with an avian influenza inactivated oil-emulsion vaccine. In the method, through the double effects of intraperitoneal inoculation with the inactivated antigen and intramuscular or subcutaneous injection with the inactivated oil-emulsion vaccine on the ducklings, the ducklings can quickly produce an immune response so as to quickly produce the anti-avian influenza antibodies; and the immune dead time of the ducklings immunized with the avian influenza inactivated vaccine can be effectively reduced by more than 7 days.

First claim

We claim:

1. A method for enabling ducklings to produce anti-avian influenza antibodies and maintain antibody titer, comprising: step 1) performing first immunization on ducklings at the age of 5 to 15 days by inoculating each duckling with an avian influenza inactivated antigen into an abdominal cavity, and simultaneously intramuscularly or subcutaneously immunizing each duckling with an avian influenza inactivated oil-emulsion vaccine.

2. The method according to claim 1 , wherein in step 1), the first immunization is performed on the ducklings at the age of 18 to 10 days.

3. The method according to claim 1 , wherein, in step 1), the dosage of the inactivated antigens is 0.1 to 1 mL, and an anti-avian influenza virus antibody titer after inoculation is 7 Log2 to 12 Log2 according to hemagglutination assay.

4. The method according to claim 1 , wherein, in step 1), the dosage of the inactivated antigens is 0.3 mL to 0.5 mL, and the anti-avian influenza virus antibody titer after inoculation is 9 Log2 to 10 Log2 according to the hemagglutination assay.

5. The method according to claim 1 , wherein, in step 1), the dosage of the inactivated oil-emulsion vaccines is 0.1 mL to 1 mL, and an anti-avian influenza virus antibody titer after immunization is 7 Log2 to 12 Log2 according to hemagglutination inhibition assay.

6. The method according to claim 1 , wherein, in step 1), the dosage of the inactivated oil-emulsion vaccines is 0.3 mL to 0.5 mL, and the anti-avian influenza virus antibody titer after immunization is 9 Log2 to 10 Log 2 according to the hemagglutination inhibition assay.

7. The method according to claim 1 , further comprising: step 2) re-immunizing the ducklings after 10 days from the first immunization by inoculating each duckling with the avian influenza inactivated antigen into the abdominal cavity.

8. The method according to claim 7 , wherein in step 2), the dosage of the inactivated antigens is 0.1 mL to 1 mL, and the anti-avian influenza virus antibody titer after inoculation is 7 Log2 to 12 Log2 according to hemagglutination assay.

9. The method according to claim 7 , wherein, in step 2), the dosage of the inactivated antigens is 0.3 mL to 0.5 mL, and the anti-avian influenza virus antibody titer after inoculation is 9 Log2 to 10 Log2 according to the hemagglutination assay.

10. The method according to claim 1 , wherein in the step 1), strains of the inactivated antigens comprise an H5 subtype avian influenza strain and an H9 subtype avian influenza strain; and a production strain of the inactivated oil-emulsion vaccine comprises an H5 subtype avian influenza strain and an H9 subtype avian influenza strain.

Assignees

• Zhaoqing Dahuanong Biological Medicine Co Ltd
• Univ South China Agricult

Inventors

• Chen Ruiai
• Zhang Aiguo
• Liu Yufu
• Xu Jiahua
• Zhang Shuqiong
• Huang Wenke
• Wu Daxing
• Liao Shichang

Classifications

• A61K2039/552

  Veterinary vaccine · CPC title

• A61K2039/543

  intranasal · CPC title

• C12N2760/16171

  Demonstrated in vivo effect · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title